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Background: The Ts1Cje mouse model of Down syndrome (DS) has partial triplication of mouse chromosome 16
(MMU16), which is partially homologous to human chromosome 21. These mice develop various neuropathological
features identified in DS individuals. We analysed the effect of partial triplication of the MMU16 segment on global
gene expression in the cerebral cortex, cerebellum and hippocampus of Ts1Cje mice at 4 time-points: postnatal day
(P)1, P15, P30 and P84.
Results: Gene expression profiling identified a total of 317 differentially expressed genes (DEGs), selected from
various spatiotemporal comparisons, between Ts1Cje and disomic mice. A total of 201 DEGs were identified from
the cerebellum, 129 from the hippocampus and 40 from the cerebral cortex. Of these, only 18 DEGs were identified
as common to all three brain regions and 15 were located in the triplicated segment. We validated 8 selected DEGs
from the cerebral cortex (Brwd1, Donson, Erdr1, Ifnar1, Itgb8, Itsn1, Mrps6 and Tmem50b), 18 DEGs from the
cerebellum (Atp5o, Brwd1, Donson, Dopey2, Erdr1, Hmgn1, Ifnar1, Ifnar2, Ifngr2, Itgb8, Itsn1, Mrps6, Paxbp1, Son, Stat1,
Tbata, Tmem50b and Wrb) and 11 DEGs from the hippocampus (Atp5o, Brwd1, Cbr1, Donson, Erdr1, Itgb8, Itsn1,
Morc3, Son, Tmem50b and Wrb). Functional clustering analysis of the 317 DEGs identified interferon-related signal
transduction as the most significantly dysregulated pathway in Ts1Cje postnatal brain development. RT-qPCR and
western blotting analysis showed both Ifnar1 and Stat1 were over-expressed in P84 Ts1Cje cerebral cortex and
cerebellum as compared to wild type littermates.
Conclusions: These findings suggest over-expression of interferon receptor may lead to over-stimulation of Jak-Stat
signaling pathway which may contribute to the neuropathology in Ts1Cje or DS brain. The role of interferon mediated
activation or inhibition of signal transduction including Jak-Stat signaling pathway has been well characterized in
various biological processes and disease models including DS but information pertaining to the role of this pathway in
the development and function of the Ts1Cje or DS brain remains scarce and warrants further investigation.* Correspondence: lkh@upm.edu.my; hamish.scott@health.sa.gov.au
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Down Syndrome (DS) is a genetic disorder resulting from
trisomy or partial trisomy of human chromosome 21
(HSA21). This syndrome is a non-heritable genetic dis-
order that occurs at a prevalence of approximately 1 in
750 live births [1]. DS has been associated with more than
80 clinical manifestations, including cognitive impairment
or intellectual disability, craniofacial features, cardiac ab-
normalities, hypotonia and early onset Alzheimer’s disease
[2,3]. In terms of cognitive impairment, DS individuals
have an average Intelligence Quotient (IQ) value of 50 [4]
as well as learning impairment involving both long-term
and short-term memory [5]. DS individuals also present
with reduced brain size, brain weight, brain volume, neur-
onal density, and neuronal distribution with neurons that
are characterized by shorter dendritic spines, reduced
dendritic arborization and synaptic abnormalities [6-8].
There are various hypotheses that attempt to explain
the genotype-phenotype relationship of DS. The gene
dosage imbalance hypothesis states that an increased
copy number of genes on HSA21 leads to an overall in-
crease in gene and protein expression and a subset of
these directly result in the traits associated with DS [1].
In contrast, the amplified developmental instability hy-
pothesis suggests that the dosage imbalance of genes on
HSA21 results in a general disruption of genomic regu-
lation and expression of genes involved in development,
which upsets normal homeostasis and results in many of
the traits associated with DS [9]. A further proposed hy-
pothesis is known as the critical region hypothesis and is
based on genetic analyses performed on individuals with
partial trisomy of HSA21. This line of thinking suggests
that a small set of genes within the Down Syndrome
Critical or Chromosomal Region (DSCR) are responsible
for the development of common DS phenotypes [10].
However, this hypothesis is not supported by experi-
ments on DS individuals, which demonstrated that the
DSCR is more likely to be a susceptible region for DS
phenotypes, rather than a single critical region causing
all DS phenotypes [11-13]. In reality, it is unlikely that
the DS traits are caused by one genetic mechanism but
instead are due to a combination of mechanisms, with
the added complexity of further genetic and epigenetic
controls [14]. Some researchers have suggested that dos-
age imbalance of certain genes may not have any effect
on the DS phenotype as they are “dosage compensated”
under certain circumstances [1].
Significant genetic homology exists between HSA21
and mouse chromosome 16 (MMU16) [15], MMU17
and MMU10 [16], which has allowed the generation of
mouse models of DS and testing of genotype-phenotype
correlation hypotheses. There are a few strains of mice
that are trisomic for segments of MMU16 that are hom-
ologous to HSA21 including Ts65Dn [mitochondrialribosomal protein L39, (Mrpl39)-zinc finger protein 295,
(Znf295)] [17], Ts1Yey [RNA binding motif protein 11,
(Rbm11)-Znf295] [18], Ts1Cje [superoxide dismutase 1,
soluble, (Sod1)-Znf295] [19] and Ts1Rhr [carbonyl reduc-
tase 1, (Cbr1)- myxovirus (influenza virus) resistance 2,
(Mx2)] [12] strains. In addition, the Ts2Yey [protein argin-
ine N-methyltransferase 2, (Prmt2)-pyridoxal (pyridoxine,
vitamin B6) kinase, (Pdxk)] strain [20] is trisomic for
MMU10 segments, whereas the Ts3Yey [ribosomal RNA
processing 1 homolog B (S. cerevisiae), (Rrp1b)-ATP-bind-
ing cassette, sub-family G (WHITE), member 1, (Abcg1)]
[20] and Ts1Yah [U2 small nuclear ribonucleoprotein
auxiliary factor (U2AF) 1, (U2af1)-Abcg1] [21] strains are
trisomic for segments of MMU17. Each of these mouse
models was found to perform differently in cognitive and
hippocampal long-term potentiation (LTP) or long-term
depression (LTD) tests and exhibit differences in brain
morphology and behavioural phenotypes as well as neuro-
pathology [22]. As such, there is currently no perfect
mouse model to study the DS brain. In 2010, Yu and col-
leagues [20] generated a mouse model [Dp(10)1Yey/+;Dp
(16)1Yey/+;Dp(17)1Yey/+] with regions that are syntenic
to all of HSA21. This mouse model is characterised by
several DS-related neuropathological features including
cognitive impairment and reduced hippocampal LTP. Un-
fortunately, the mice develop hydrocephalus, a phenotype
that is rarely associated with DS, and 25% of these animals
die between 8 to 10 weeks of age [20].
The Ts1Cje mouse model, also known as T(12;16)1Cje,
was developed in 1998 and carries a partial trisomy of
MMU16 resulting from a translocation of a segment of
MMU16 spanning across the superoxide dismutase 1
(Sod1) gene to the zinc finger protein 295 (Znf295) gene
onto MMU12 [19,23]. This trisomic region is syntenic to
HSA21. Recent literature reports a significant correlation
between Ts1Cje mice phenotypes and DS individuals, in-
cluding altered hippocampus-dependent learning and
memory [24-26], craniofacial defects [27] and reduced
cerebellar volume [23,28]. This makes Ts1Cje a suitable
model to study the neurobiology networks and mecha-
nisms that contribute to the neuropathology in DS indi-
viduals. Olson and colleagues [28] reported that the
Ts1Cje mouse is defective in both prenatal and postnatal
neurogenesis. We have recently demonstrated that adult
Ts1Cje mice start with a similar number of adult neural
stem cells as their control littermates, but later develop
fewer neuronal progenitors, neuroblasts and neurons
[29]. In that study we also reported that differentiated
Ts1Cje neurons harbour fewer neurites and have an in-
creased number of astrocytes, which demonstrates that
the Ts1Cje mouse has defective neurogenesis and neuronal
development. Similar observations have been reported by
different studies that showed impaired adult neurogenesis
in the subventricular zone (SVZ) and impaired embryonic
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hippocampus also exhibits abnormal short- and long-
term synaptic plasticity [26] as well as an impairment
that is restricted to the spatially oriented domain, since
short- and long-term novel object recognition memory
is conserved [25].
Many genomic studies have been conducted on vari-
ous tissues from mouse models of DS. To date, gene ex-
pression studies on Ts1Cje have mostly been done on
the postnatal cerebellum up to day 30 [23,31,32]. Gene
expression analyses on Ts1Cje whole brain at postnatal
day 0 [33], and on neocortical neurospheres at embry-
onic day 14.5 [34] have also been reported. We have pre-
viously analysed the global gene expression in Ts1Cje
adult neural stem cells (P84) [29]. All previous studies
have been completed on specific brain regions or the
whole brain and have not encompassed the entire post-
natal brain development period. In addition, gender
differences and hormonal influences may also be a con-
founding factor in some of these gene expression studies
as not all reported the gender of their subjects and litter-
mate controls. In order to understand the effect of seg-
mental MMU16 trisomy on the postnatal Ts1Cje brain
and the complex mechanisms that may result in neuro-
pathology, we performed a comprehensive spatiotempo-
ral gene expression profiling analysis of 3 brain regions
(cerebral cortex, cerebellum and hippocampus) at 4 dif-
ferent time points (Postnatal day (P)1, P15, P30 and
P84). These regions were selected for analysis as they are
most commonly reported to be affected by neuropathol-
ogy in DS and mouse models [35]. Furthermore, mice at
postnatal day (P)1, P15, P30 and P84, correspond to
postnatal brain development and function during the
neonatal, juvenile, young adult and adult periods.
Methods
Ethics statement, animal breeding, handling and
genotyping
Breeding procedures, husbandry and all experiments
performed on mice used in this study were carried out
according to protocols approved by the Walter and Eliza
Hall Institute Animal Ethics Committee (Project numbers
2001.45, 2004.041 and 2007.007) and the Faculty of Medi-
cine and Health Sciences, Universiti Putra Malaysia Animal
Care and Use (ACU) committee (Approval reference: UPM/
FPSK/PADS/BR-UUH/00416). All sex matched disomic
and trisomic littermates involved in the study were gener-
ated by mating Ts1Cje males with C57BL/6 female mice.
All mice were kept in a controlled environment with
an equal light/dark cycle. Unlimited standard pellet diet
and water were provided. Genomic DNA was extracted
from mouse-tails and genotyped using multiplex PCR
primers for neomycin (neo) and glutamate receptor, iono-
tropic, kainite 1 (Grik1) as an internal control as describedpreviously [19] with substitution of gel electrophoresis
with high resolution melting analysis.
Tissue procurement, RNA extraction, quality control and
microarray analysis
Procurement of the cerebral cortex, hippocampus and
cerebellum were performed on 3 Ts1Cje and 3 disomic
female littermates at 4 time points (P1.5, P15, P30 and
P84) according to a method described previously [36].
Only female mice were utilized in the study to avoid the
downstream effects of Y-linked genes on neural sexual
differentiation [37]. Total RNA was purified from each
tissue, with assessment of RNA quality and quantifica-
tion of purified RNA performed according to methods
described previously [29]. Each RNA sample was proc-
essed using the Two-Cycle Target Labeling Assay and
hybridized onto Affymetrix Gene-Chip® Mouse Genome
430 2.0 arrays (Affymetrix, USA) according to the manu-
facturer’s protocols. Fluorescent signals were detected
using a GeneChip® Scanner 3000 (Affymetrix, USA) and
expression data were pre-processed and normalized
using the gcRMA algorithm [38]. All datasets were nor-
malized by comparing Ts1Cje trisomic mouse brains to
their disomic littermates.
Differentially expressed genes (DEGs), gene ontology and
pathway analyses
The Empirical Bayes t-statistic [39] was used to analyse
differential expression of genes between groups according
to a method described previously [29]. Briefly, stringent
criteria were employed to select differentially expressed
genes (DEGs) from the analysis including t-statistic values
of ≥ 4 or ≤ −4 and an adjusted P-value of ≤ 0.05. Selected
DEGs were collectively analysed for functional ontologies
using the Database for Annotation, Visualisation and Inte-
grated Discovery (DAVID) [40]. High classification strin-
gency was used to analyse the gene lists with the following
settings; a kappa similarity threshold of 0.85, a minimum
term overlap of three, two initial and final group member-
ship with 0.50 multiple linkage threshold and a modified
Fisher-exact p-value or enrichment thresholds of 0.05. All
DEGs were analysed according to brain regions and/or
time-points.
Quantitative real time polymerase chain reaction (RT-qPCR)
RT-qPCR was performed to validate the expression of
DEGs using cDNAs that were generated from the same
RNAs used for microarray analysis. First strand cDNA
was synthesized from 3000 ng total RNA using random
hexamers and the SuperScript™III Reverse Transcriptase
Kit (Invitrogen, USA) according to the manufacturer’s
protocol. Primers were designed and probes selected
using ProbeFinder version 2.34 (except for Stat1 where
ProbeFinder version 2.45 was used) at the Universal
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http://lifescience.roche.com/). RT-qPCR was performed in
triplicate using the LC480 Master Probe Mix (Roche
Diagnostics, Switzerland) and Universal ProbeLibrary
(UPL) probe (Roche Diagnostics, Australia) according to
published methods [29,36] (see Additional file 1 for a full
list of primers and UPL probes used). Conditions for the
RT-qPCR, calculation of quantification cycle for each
signal, determination of PCR efficiencies, reproducibil-
ity (R2 values) and relative quantification of target gene
expression in Ts1Cje and disomic samples were per-
formed essentially according to methods described previ-
ously [36]. Successful assays were defined by a PCR
efficiency of between 90-110% and an R2 values > 0.98.
Western blotting
Cerebral cortices and cerebella were harvested from 3
adult (P84) Ts1Cje and 3 wild type mice. The samples
were homogenised and lysates extracted in 1X radioim-
munoprecipitation assay (RIPA) lysis buffer (Millipore,
USA) containing protease inhibitor cocktail set III (Cal-
biochem, USA). Protein concentration was analysed using
Coomassie Plus (Bradford) Assay reagent according to
manufacturer’s protocol (Thermo Scientific, USA). Protein
samples were then separated by 8% SDS-PAGE and
Western blots were performed. For immunodetection, the
following antibodies were used: anti-Stat1 (#9172; Cell
Signaling Technology, USA; 1:200 dilution), anti-Ifnar1
(#127322; Biolegend, USA; 1:200 dilution), anti-Ifnar2 (sc-
20218; Santa Cruz, USA; 1:200 dilution), and anti-β-actin
(ab8227; Abcam, UK; 1:1000 dilution). Blots were incu-
bated overnight at 4°C with primary antibodies followed
by 1 hour incubation at room temperature with HRP-
conjugated secondary antibodies. The following secondary
antibodies were used: anti-goat (CGHL-50AX809015,
ICL. Inc., USA), anti-mouse (sc-2005, Santa Cruz, USA)
and anti-rabbit (#406401, Biolegend, USA) (all at 1:2500
dilution). Immunoreactivity was visualized using the
WesternBright™ Quantum™ (Advansta Corp., USA) for
β-actin and WesternBright™ Sirius™ (Advansta Corp., USA)
for Stat1, Ifnar1 and Ifnar2. Pixelation analyses of bands
were performed using ImageJ software according to the
standard protocol published at http://rsb.info.nih.gov/ij.
Results
Microarray datasets and differentially expressed genes
(DEGs)
To investigate the effect of partial trisomy on postnatal
brain development and function in Ts1Cje mice, we per-
formed 72 whole-genome expression analyses using
GeneChip® Mouse Genome 430 2.0 Arrays (Affymetrix,
Santa Clara, USA). The analyses encompassed compari-
son of three brain regions (cerebral cortex, cerebellum
and hippocampus) at 4 different time points (Postnatal(P)1, P15, P30 and P84) in Ts1Cje and disomic female
mice. These datasets are publicly accessible from the
Gene Expression Omnibus website under the series ac-
cession number GSE49050 (http://www.ncbi.nlm.nih.gov/
geo/query/acc.cgi?acc=GSE49050).
To investigate the overall characteristics of genes in
the trisomic region, we plotted their log2 fold-change
(M) for trisomic versus disomic mice versus the average
log2 expression (A) (Figure 1). Probe-sets that were not
expressed or showed no differences between the groups
of mice were plotted near to 0. There was consistently a
larger number of probe-sets located in the trisomic re-
gion with M values greater than 0.58, signifying their
1.5-fold upregulation in various brain regions and devel-
opmental stages compared to probe-sets located in di-
somic regions of the genome. Our observation therefore
supports the gene dosage imbalance hypothesis, which
specifies that an increased copy number of genes will
lead to an overall increase in their expression by 50%.
Genes located within the trisomic region have an in-
creased copy number of 0.5 compared to genes located
within disomic regions. According to the gene dosage im-
balance hypothesis, we expect only a small fold-change dif-
ference in the level of gene expression between Ts1Cje and
disomic groups resulting in a small number of globally dif-
ferentially expressed genes (DEGs) based on our stringent
selection criteria (see Methods). The analysis revealed 317
DEGs based on all spatiotemporal comparisons completed
between the Ts1Cje and disomic mice (Table 1; Additional
file 2). Of these DEGs, 41 are located on the MMU16 trip-
licated segment (Table 2) and all of the significant probe
sets were found to be upregulated by 1.4- – 4.8-fold, which
again supports the gene dosage imbalance hypothesis.
When we considered only spatial comparisons (regard-
less of time point), 40 DEGs were identified from the
cerebral cortex, 201 from the cerebellum and 129 from
the hippocampus. Of these DEGs, 16, 33 and 33 were lo-
cated on the MMU16 triplicated region in the cerebral
cortex, cerebellum and hippocampus regions, respect-
ively. We identified 19, 168 and 95 region-specific DEGs
for the cerebral cortex, cerebellum and hippocampus, re-
spectively (Figure 2). These observations suggest that the
partial trisomy of MMU16 in Ts1Cje mice has a greater
effect on gene regulation in the hippocampus and cere-
bellum as compared to the cerebral cortex. Of all of the
DEGs identified, only 18 were found to be common to
all three-brain regions [ATP synthase, H + transporting,
mitochondrial F1 complex, O subunit, Atp5o; bromodo-
main and WD repeat domain containing 1, Brwd1; chro-
matin assembly factor 1, subunit B (p60), Chaf1b;
crystallin, zeta (quinone reductase)-like 1,Cryzl1; dynein,
axonemal, heavy chain 11, Dnah11; downstream neigh-
bor of SON, Donson; dopey family member 2, Dopey2;
erythroid differentiation regulator 1, Erdr1; interferon
Figure 1 MA plots of trisomic and disomic microarray probe-sets from 3 different brain regions (cerebral cortex, cerebellum and
hippocampus) at 4 postnatal (P) time points (P1, P15, P30 and P84). The Y-axis represents the M value, which is the ratio (log2(T/D)) whereas
the X-axis represents the A value, which is the mean ratio (1/2xlog2(TxD)). T and D represent the intensities of microarray probe-sets for Ts1Cje
and disomic samples, respectively. Each blue dot represents a single probe. Red dotted lines denote the cutoff at M values of 0.58, signifying
1.5-fold upregulation of microarray probe-sets.
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beta) receptor 2, Ifnar2; integrin beta 8, Itgb8; intersectin
1 (SH3 domain protein 1A), Itsn1; microrchidia 3, Morc3;
mitochondrial ribosomal protein S6, Mrps6; phospha-
tidylinositol glycan anchor biosynthesis, class P, Pigp; pro-
teasome (prosome, macropain) assembly chaperone 1,
Psmg1; transmembrane protein 50B, Tmem50b and tetra-
tricopeptide repeat domain 3,Ttc3]. Interestingly, 15 out of
these 18 DEGs were located in the MMU16 triplicated re-
gion (Additional file 2), suggesting that these trisomic genes
could be responsible for the global dysregulation of other
DEGs within the Ts1Cje brain throughout development.Functional clustering of DEGs based on gene ontologies
To dissect the ontologies that are enriched in the list of
DEGs, we employed a top-down screening approach to
analyze any disrupted molecular networks on a global
level, followed by refined analyses involving specific
brain regions or developmental stages. An initial analysis
of the 317 DEGs revealed 7 significant functional clus-
ters that were associated with interferon-related signal-
ing pathways (23 DEGs, 6 ontologies), innate immune
pathways (9 DEGs, 4 ontologies), Notch signaling path-
way (4 DEGs, 1 ontology), neuronal signaling pathways
(9 DEGs, 2 ontologies), cancer-related pathways (11
Table 1 Summary of microarray analysis
Time-point Region P1 P15 P30 P84 Total number of unique DEGs
Cerebral Cortex Probe set 20 5 15 20 40
DEG 12↑ 8↓ 4↑ 1↓ 13↑ 2↓ 13↑ 6↓
Cerebellum Probe set 117 53 18 93 201
DEG 46↑ 66↓ 43↑ 1↓ 12↑ 4↓ 64↑ 23↓
Hippocampus Probe set 28 59 22 81 129
DEG 22↑ 4↓ 48↑ 3↓ 20↑ 1↓ 69↑ 7↓
Total number of unique DEGs 131 80 30 145 (317)
↑ denotes ‘upregulation’, ↓ denotes ‘downregulation’, DEG denotes ‘differentially expressed gene’ and P denotes ‘postnatal day’. The value in parentheses denotes
non-redundant unique DEGs based on the spatiotemporal comparison between Ts1Cje and disomic mice.
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(3 DEGs, 2 ontologies) and dynamic regulation of cyto-
skeleton pathways (7 DEGs, 2 ontologies). The func-
tional clustering analysis was repeated using the lists of
DEGs from each brain region regardless of developmen-
tal stage and subsequently at each developmental stage.
The DEGs found at each developmental stage were
found to be significantly enriched for the same pathways
identified in the list of 317 DEGs (see Additional file 3).
The results of the top-down functional screening ap-
proach are illustrated in Figure 3.
Based on the analysis involving all 317 DEGs, only 3,
namely Ifnar1, Ifnar2 and interferon gamma receptor
2 (Ifngr2), from the triplicated MMU16 region were
enriched in the functional clusters that were identified
(Figure 3). These DEGs were found within two annotation
clusters for six interferon-related signaling pathways, in-
cluding the interferon alpha signaling pathway, natural
killer cell mediated cytotoxicity, cytokine-cytokine recep-
tor interaction, toll-like receptor signaling pathway, the
Janus kinase (Jak)-signal transducer and activation of tran-
scription (Stat) signaling pathway and the inflammation
mediated by chemokine and cytokine signaling pathways.
Interestingly, these DEGs are surface interferon receptors
and were also found to be enriched for the same func-
tional clusters in all regions of the brain assessed regard-
less of developmental stage. This suggests that trisomy of
Ifnar1, Ifnar2 and Ifngr2 is crucial in causing dysregulation
of interferon-related pathways, which may in turn contrib-
ute to the developmental and functional deficits in
the Ts1Cje brain. Disomic DEGs that were clustered with
the 3 interferon receptors include activin receptor IIB
(Acvr2b), caspase 3 (Casp3), collagen, type XX, alpha 1
(Col20a1), ectodysplasin A2 isoform receptor (Eda2r), epi-
dermal growth factor receptor (Egfr), c-fos induced growth
factor (Figf ), growth differentiation factor 5 (Gdf5), histo-
compatibility 2, K1, K region (H2-K1), interleukin 17 re-
ceptor A (Il17ra), interferon regulatory factor 3 (Irf3),
interferon regulatory factor 7 (Irf7), inositol 1,4,5-triphos-
phate receptor 3 (Itpr3), lymphocyte cytosolic protein 2
(Lcp2), leptin receptor (Lepr), nuclear factor of activatedT-cells, cytoplasmic, calcineurin-dependent 4 (Nfatc4),
regulator of G-protein signaling 13 (Rgs13), signal trans-
ducer and activator of transcription 1 (Stat1) and Tnf
receptor-associated factor 6 (Traf6). We consider these as
important candidates for further analysis to understand
the neuropathology of DS. We propose that differential
regulation of these disomic genes will lead to a number of
further cascades of low-level gene dysregulation within
the Ts1Cje brain. For example, we found Egfr to be inter-
connected in various dysregulated molecular pathways
represented by different functional clusters including the
calcium signaling pathway, neuroactive ligand-receptor
interaction and the MAPK signaling pathway, as well as
pathways in cancers such as pancreatic and colorectal can-
cers, which involve focal adhesion and regulation of actin
cytoskeleton (Figure 3).
We were also interested to elucidate all potential mo-
lecular pathways represented by the 18 DEGs that were
common to all brain regions analysed throughout devel-
opment (Atp5o, Brwd1, Chaf1b, Cryzl1, Dnah11, Donson,
Dopey2, Erdr1, Ifnar1, Ifnar2, Itgb8, Itsn1, Morc3, Mrps6,
Pigp, Psmg1, Tmem50b and Ttc3). Functional clustering
analysis of these genes showed that interferon-related
pathways were enriched, which was mainly attributed to
the presence of Ifnar1 and Ifnar2. Combining our func-
tional analyses, our data suggest that interferon-related
pathways are globally dysregulated and therefore import-
ant in causing neurological deficits within the Ts1Cje
mouse brain.
RT-qPCR validation of selected DEGs
RT-qPCR was used to validate the DEGs identified in
the microarray comparisons. We focused on validating
DEGs that were located within the triplicated MMU16
region, which were common to all brain regions ana-
lysed and those that were involved in interferon-related
pathways. Twenty five genes (actin, gamma, cytoplasmic
1, (Actg1); Atp5o; Brwd1; Cbr1; Donson; Dopey2; Erdr1;
high mobility group nucleosomal binding domain 1,
(Hmgn1); Ifnar1; Ifnar2; Ifngr2; Itgb8; Itsn1; potassium
inwardly-rectifying channel, subfamily J, member 6, (Kcnj6);
Table 2 Summary of spatiotemporal microarray profiling of 41 DEGs found in the triplicated segment of MMU16
Full gene name
(Official gene symbol) Probe set ID
Log2 expression of Ts1Cje normalized against disomic littermates
Cerebral cortex Cerebellum Hippocampus
P1 P15 P30 P84 P1 P15 P30 P84 P1 P15 P30 P84
RIKEN cDNA 1110004E09Rik
gene (1110004E09Rik)
1424315_at 0.72 0.70 0.67 0.73 1.39* 0.91 0.91 0.70 0.61 1.12 0.97 0.83
RIKEN cDNA 2410124H12Rik
gene (2410124H12Rik)
1432515_at 0.03 0.09 0.01 0.16 0.07 1.68** 1.51*** 2.26*** -0.02 -0.08 0.05 -0.14
ATP synthase, H+ transporting,
mitochondrial F1 complex,
O subunit (Atp5o)
1416278_a_at 0.65 0.49 0.70 0.48 0.43 0.67 0.82* 0.54 0.68 0.37 0.48 1.09***




1450528_at 0.00 0.02 -0.02 0.00 0.02 0.15 -0.01 0.43 -0.02 -0.11 0.15 1.25*
Expressed sequence BF642829
(BF642829)
1435484_at 0.56 0.34 0.68 -0.04 0.91** 0.75* 0.68 0.01 0.59 0.69 0.89** 0.17
Bromodomain and WD repeat
domain containing 1 (Brwd1)
1427322_at 0.67 0.45 0.50 0.40 0.32 0.81* 0.84* 0.54 0.78 0.26 0.52 1.11***
1433955_at 0.55 0.53 0.63 0.86* 1.17*** 0.81** 0.57 1.01*** 0.39 0.70* 0.70* 0.91***
1452322_a_at 0.07 0.62 0.47 0.83* 0.14 0.37 0.22 0.94*** 0.67* 0.46 0.68* 0.22
C2 calcium-dependent domain
containing 2 (C2cd2)
1436344_at 0.47 0.47 0.38 0.54 0.27 1.87*** 0.47 0.74 0.39 0.71 0.91 0.68
1437731_at 0.79 0.30 0.15 0.47 0.59 1.21* 0.18 0.45 0.58 0.32 0.55 0.18
Carbonyl reductase 1 (Cbr1) 1460196_at 0.67 0.48 0.66 0.58 0.71 0.52 0.30 0.72* 0.64 0.95** 0.72 0.74*
Carbonyl reductase 3 (Cbr3) 1427912_at 1.55 1.11 0.82 0.81 1.08 -0.02 0.21 0.79 1.24 2.04* 1.07 0.44
Chromatin assembly factor 1,
subunit B (p60) (Chaf1b)
1423877_at 1.15*** 0.10 0.00 0.08 0.93*** -0.03 -0.06 0.00 1.51*** 0.05 -0.08 -0.11
Crystallin, zeta (quinone
reductase)-like 1 (Cryzl1)
1430547_s_at 0.70 0.57 0.76 0.55 0.60 0.70 0.97 0.94* 0.57 0.17 0.37 1.28***
1451473_a_at 0.47 0.61 0.86** 0.67 0.61 0.88*** 0.49 0.51 0.57 0.82** 0.85** 0.59*
DnaJ (Hsp40) homolog,
subfamily C, member 28
(Dnajc28)
1420542_at 0.36 0.29 0.14 0.18 0.26 0.33 0.21 0.81* 0.28 0.15 0.26 0.23
Downstream neighbor of
SON (Donson)
1426739_at 0.76 0.72 0.91** 0.78 0.82* 0.91** 0.75 0.75* 0.81* 0.65 0.63 0.92**
Dopey family member 2
(Dopey2)
1428330_at 0.68* 0.47 0.61 0.45 0.58 0.83** 0.70* 0.59 1.00*** 0.68* 0.85** 0.77**
Down syndrome cell adhesion
molecule (Dscam)
1441082_at 0.35 0.70 1.13 0.78 0.41 0.36 0.94 0.74 0.40 1.60** 1.13 0.59
1449411_at 0.94 0.83 0.98 1.03 0.69 0.54 0.70 1.22* 0.81 1.52** 0.87 0.86
1458625_at 0.52 0.44 0.74 0.72 0.79 0.11 0.33 0.50 0.72 1.65*** 1.39** 0.45
Down syndrome critical region
3 (Dscr3)
1415745_a_at 0.87 0.74 0.66 0.91 0.97* 0.93* 0.87 0.66 0.80 0.89* 1.01* 0.94*
E26 avian leukemia oncogene
2, 3' domain (Ets2)
1416268_at 0.78 0.62 0.81 0.56 0.54 0.87* 0.65 0.80* 0.62 0.45 0.68 0.77
Phosphoribosylglycinamide
formyltransferase (Gart)
1416283_at 0.52 0.38 0.92 0.37 0.39 1.17** 0.54 0.93 0.70 0.95 1.20* 0.95




1422495_a_at 0.51 0.60 0.59 0.55 0.22 0.96** 0.49 0.68* 0.36 0.16 0.64 0.82**
1438940_x_at 0.39 0.52 0.50 0.67 0.40 0.76* 0.24 0.54 0.39 0.33 0.50 0.36
1455897_x_at 0.44 0.69 0.70 0.95 0.49 1.07** 0.30 0.80 0.40 0.52 0.87 0.58
Hormonally upregulated
Neu-associated kinase (Hunk)
1418260_at 0.66 0.66 0.25 0.68 0.41 0.83 0.87 0.64 1.10* 0.52 0.61 1.16**
Interferon (alpha and beta)
receptor 1 (Ifnar1)
1442222_at 0.63 0.74 1.05 0.77 0.45 1.12* 0.73 0.68 0.62 0.80 0.80 0.75
1449026_at 0.80 0.80 1.17* 1.29* 0.55 0.67 0.85 1.10* 0.46 1.12* 0.84 0.75
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Table 2 Summary of spatiotemporal microarray profiling of 41 DEGs found in the triplicated segment of MMU16
(Continued)
Interferon (alpha and beta)
receptor 2 (Ifnar2)
1427691_a_at 0.66 0.52 0.67 0.40 0.55 0.80 0.48 0.58 0.73 1.49* 0.91 0.50
1440169_x_at 0.72 0.92 0.78 0.60 0.89 0.68 0.45 0.34 1.22 1.49* 0.84 0.62
1451462_a_at 0.70 0.90 0.99* 0.98 0.61 0.90* 0.80 0.93* 0.81 0.83 0.92* 1.43***
Interferon gamma receptor
2 (Ifngr2)
1423558_at 0.31 0.39 0.40 0.44 0.67** 0.14 0.17 0.21 0.21 0.45 0.28 0.26
Intersectin 1 (SH3 domain
protein 1A) (Itsn1)
1421192_a_at 0.82 0.45 0.90 0.40 0.03 0.94* 1.16** 0.66 1.01* 0.48 0.97* 1.04**
1425899_a_at 0.58 0.61 0.71 0.22 0.35 0.72 1.37 0.90 0.76 -0.54 0.18 1.67*
1435885_s_at 0.56 0.61 0.63 0.66** 0.46 1.18* 0.25 0.50 0.49 0.37 0.97 0.21
1452338_s_at 0.58 0.96 1.42** 1.66 0.44 0.99 0.80 1.30** 0.64 0.25 0.70 0.74
Potassium inwardly-rectifying
channel, subfamily J, member
6 (Kcnj6)
1425707_a_at -0.13 0.24 0.22 0.59 0.18 0.29 0.04 0.31 -0.21 0.57 1.07* -0.06
Microrchidia 3 (Morc3)
1420091_s_at 0.55 0.81** 0.64 0.66 0.78** 0.84*** 0.69* 0.55 0.64* 0.66* 0.78** 0.99***
1452224_at 0.69 0.64 0.68 0.66 0.82 0.99 1.21* 0.52 1.20* 0.51 0.55 1.45**
Mitochondrial ribosomal
protein S6 (Mrps6)
1424440_at 0.84** 0.62 0.73 0.35 0.89** 0.70* 0.89** 1.00*** 0.77* 0.72* 0.64 0.91**
1447585_s_at 0.93 0.74 0.88 0.74 1.13* 0.88 0.53 0.94 0.61 1.15* 0.91 0.61
PAX3 and PAX7 binding
protein 1 (Paxbp1)
1418007_at 0.55 0.66 0.75 0.59 0.55 1.32* 0.59 0.80 0.83 0.15 0.80 0.56




1436038_a_at 0.69* 0.70 0.77* 0.95** 0.77** 0.75** 0.84** 0.82*** 0.38 0.54 0.55 1.16***
PR domain containing 15
(Prdm15)
1455459_at 0.41 -0.04 0.47 0.59 0.21 0.37 0.59 0.18 0.44 0.48 0.35 0.95*
Proteasome (prosome,
macropain) subunit,
alpha type 2 (Psmg1)
1448307_at 0.81* 0.52 0.78 0.97* 0.73 0.99** 0.57 0.88** 0.55 1.04** 0.82* 0.94**
Regulator of calcineurin 1
(Rcan1)




1418488_s_at 0.06 0.07 0.00 0.12 0.12 -0.02 0.06 0.02 0.53*** 0.02 -0.05 -0.09
Solute carrier family 5 (inositol
transporters), member 3 (Slc5a3)
1435484_at 0.56 0.34 0.68 -0.04 0.91*** 0.75*** 0.68 0.01 0.59 0.69 0.89*** 0.17
Small integral membrane
protein 11(Smim11)
1417402_at 0.85 0.43 0.64 0.40 0.90* 0.69 0.59 0.59 0.77 0.37 0.68 0.70
Son cell proliferation
protein (Son)
1420952_at 0.68 0.69 0.90 0.86 0.36 1.28* 0.71 0.87 0.88 0.54 0.77 0.65
1435862_at 0.64 0.75 0.80 0.63 0.35 1.04** 1.24*** 0.78 0.99* 0.20 0.58 1.17**
1437924_at 0.63 0.62 0.79 0.82 0.28 0.96** 0.75 0.67 0.35 0.60 0.65 0.73
Synaptojanin 1 (Synj1)
1436333_a_at 0.67 0.65 0.77 0.84 0.89 0.57 0.74 0.84 0.74 1.38* 0.79 0.72
1454961_at 0.60 0.57 0.65 0.63 0.57 0.43 0.58 0.71* 0.56 0.86** 0.55 0.67
Transmembrane protein
50B (Tmem50b)
1423707_at 0.78** 0.51 0.70* 0.46 0.83** 0.69* 1.07*** 0.71** 0.96*** 0.76** 0.84** 0.99***
Tetratricopeptide repeat
domain 3 (Ttc3)
1416484_at 0.52 0.53 0.68 0.56 0.60 0.39 0.74 0.87* 0.53 0.31 0.26 0.78
1448361_at 0.45 0.45 0.54* 0.43 0.21 0.43 0.46 0.40 0.33 0.63** 0.45 0.46
URB1 ribosome biogenesis
1 homolog (S. cerevisiae) (Urb1)
1454841_at 0.58 0.49 0.77 0.46 0.24 0.16 0.48 0.37 0.98* 0.62 0.76 0.85
Tryptophan rich basic
protein (Wrb)
1460446_at 0.62 0.64 0.63 0.74 0.72* 0.90* 0.45 0.67* 0.56 0.85** 0.69 0.70*
*p<0.05, **p<0.01 and ***p<0.001 based on Empirical Bayes t-statistic test.
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Figure 2 Venn diagrams depicting the spatiotemporal distribution of DEGs for comparison of Ts1Cje vs. disomic mice at 4 postnatal (P)
time points (P1, P15, P30 and P84). The combined Venn diagram consists of non-redundant DEGs from each brain region at all time points.
CC = Cerebral cortex; CB = Cerebellum; HIPP = Hippocampus.
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http://www.biomedcentral.com/1471-2164/15/624Morc3; Mrps6; PAX3 and PAX7 binding protein 1,
(Paxbp1); small integral membrane protein 11, (Smim11);
Sod1; Son cell proliferation protein, (Son); Stat1; Thymus,
brain and testes associated, (Tbata); Tmem50b; Ttc3 and
tryptophan rich basic protein, (Wrb)) were analysed by RT-
qPCR using the same RNA that was used for the micro-
array analyses, which consisted of triplicate samples from
Ts1Cje and disomic cerebral cortex tissues (Figure 4), cere-
bellum (Figure 5) and hippocampus (Figure 6) from the 4
postnatal stages (P1.5, P15, P30 and P84). The expression
profile of a gene was considered to be validated when both
microarray and RT-qPCR data showed a consistent direc-
tional change with fold differences ≥ 1.50 or ≤ 0.67. The
microarray data include many genes that are represented
by multiple probe-sets. For this analysis, only probe-sets
that were considered to be statistically significant for each
DEG were included. Eight of the selected DEGs were vali-
dated at various development time points in the cerebral
cortex (Brwd1, Donson, Erdr1, Ifnar1, Itgb8, Itsn1, Mrps6
and Tmem50b), 18 DEGs were validated in the cerebellum(Atp5o, Brwd1, Donson, Dopey2, Erdr1, Hmgn1, Ifnar1,
Ifnar2, Ifngr2, Itgb8, Itsn1, Mrps6, Paxbp1, Son, Stat1,Tbata,
Tmem50b and Wrb) and 11 DEGs were validated in the
hippocampus (Atp5o, Brwd1, Cbr1, Donson, Erdr1, Itgb8,
Itsn1, Morc3, Son, Tmem50b and Wrb). Detailed expression
profiles for all 25 DEGs are summarized in Table 3.
Western blotting
Both microarray and RT-qPCR analyses demonstrated sig-
nificant differences in Ifnar1, Ifnar2 and Stat1 expression
levels in the P84 cerebral cortex and cerebellum. To evalu-
ate the effect of mRNA levels on protein synthesis, we
measured the expression level of these proteins in the
cerebral cortex and cerebellum lysates prepared from P84
Ts1Cje and wild type mice (Figure 7). Based on the pixel-
ation analysis of the bands, Ifnar1 and Stat1 were found to
be significantly (p ≤ 0.05) over-expressed in the Ts1Cje
cerebellum as compared to wild type with 2.69- and 4.93-
fold increases, respectively. In Ts1Cje cerebral cortices, we
observed 1.55- and 1.73-fold upregulation of Ifnar1 and
Figure 3 Summary of functional clustering analysis of 317 DEGs using DAVID tools. Gene names in yellow denote trisomic genes. Thick
dotted lines connect the DEG cluster with their associated functional ontologies whereas the thin solid lines connect DEGs to various brain
regions. The colour of the thin solid lines corresponds to the brain regions to which they are connected. CC = Cerebral cortex; CB = Cerebellum;
HIPP = Hippocampus.
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type. However, none of them were statistically significant
based on pixelation analysis (see Additional file 4).
Discussion
This study aimed to identify disruptions in molecular path-
ways caused by the partial trisomy of mouse chromosome
16 (MMU16) harbored by Ts1Cje mice, which results in
neuropathology similar to that observed in people with DS.
We provide the most comprehensive molecular expression
catalogue for the Ts1Cje developing postnatal brain to date.
Previous studies have focused on single brain regions or the
whole brain at limited developmental stages [23,29,31-34].
We completed a stringent microarray analysis throughout
postnatal development (P1.5, P15, P30 and P84) of the
cerebral cortex, cerebellum and hippocampus of Ts1Cje
versus disomic littermates. The majority of the trisomic
probe-sets have a 0.5-fold increase in expression in Ts1Cje
mice as compared to disomic controls. Our data are in
agreement with previously reported microarray analysis in-
volving Ts1Cje and disomic littermate control primaryneural stem and progenitor cells [29] and Ts1Cje P0 mouse
whole brains [33] or the cerebellum [32], which demon-
strated a dosage-dependent over-expression of genes on the
triplicated segment of MMU16.
According to the spatial analysis, the number of DEGs
identified in the cerebellum and hippocampus was con-
sistently higher than in the cerebral cortex at all time
points. It is widely accepted that the cerebral cortex is
the most highly developed part of the brain, and is re-
sponsible for the majority of information processing and
higher cognitive functions, as well as being the most re-
cent addition in evolutionary terms. We hypothesise that
the smaller number of DEGs in this region throughout
post-natal development represents the higher level of
genetic control required for the cerebral cortex to func-
tion at a level that allows survival. Further evidence that
supports this theory includes a meta-analysis [41] dem-
onstrating that the human cortex has a reproducible
genomic aging pattern whilst the cerebellum does not.
This reproducibility reflects a higher level of gene expres-
sion control in the cortex compared to the cerebellum
Figure 4 RT-qPCR validation of selected DEGs in the cerebral cortex. Red lines or asterisks denote RT-qPCR data whereas black lines or
asterisks denote microarray data. *p < 0.05, **p < 0.01 and ***p < 0.001 based on Empirical Bayes t-statistic test.
Figure 5 RT-qPCR validation of selected DEGs in the cerebellum. Red lines or asterisks denote RT-qPCR data whereas black lines or asterisks
denote microarray data. *p < 0.05, **p < 0.01 and ***p < 0.001 based on Empirical Bayes t-statistic test.
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Figure 6 RT-qPCR validation of selected DEGs in the hippocampus. Red lines or asterisks denote RT-qPCR data whereas black lines or asterisks
denote microarray data. *p < 0.05, **p < 0.01 and ***p < 0.001 based on Empirical Bayes t-statistic test.
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tain a certain level of function.
The Ts1Cje mouse model contained a partial mono-
somy of MMU12 following partial translocation of
MMU16 onto this site. An ~2 MB segment of the telo-
meric end of MMU12 is deleted [23], and consequently
seven genes were deleted (Abcb5, Dnah11, Itgb8, Macc1,
Sp4, Sp8, and Tmem196) [42]. Our data showed that dy-
nein axonemal heavy chain 11 (Dnah11) is significantly
up-regulated in all three brain regions and four postnatal
developmental time points with a log2 expression ratio
that ranged from 5.4 to 7.7. This over-expression of
Dnah11 is consistent with previously reported cerebel-
lum microarray expression results [23] and this over-
expression is probably specific to the Ts1Cje mouse
model [23,33] since similar over-expression in DS pa-
tients or the Ts65Dn mouse model has not been ob-
served [43-46]. Over-expression of the Dnah11 gene is
likely caused by the position effect of an upstream regu-
latory element following translocation onto MMU12 in
the Ts1Cje genome. In our study, the expression levels
of Sp8 and Itgb8 are down-regulated (Additional file 2:
Table S2) as they are monosomic in Ts1Cje [42]. Sp8,
trans-acting transcription factor 8, is important for pat-
terning in the developing telencephalon, specification
of neuronal populations [47] and also neuromesodermal
stem cell maintenance and differentiation via Wnt3a
[48]. Meanwhile, Itgb8, Intergrin beta 8, is crucial forneurogenesis and neurovascular homeostasis regula-
tion [49]. This down-regulation of Sp8 and Itgb8 may
affect DS neuropathology features to a certain extent in
the Ts1Cje mouse brain. The remaining four monosomic
genes in Ts1Cje mice [(ATP-binding cassette, sub-family B
(MDR/TAP), member 5, (Abcb5); metastasis associated in
colon cancer 1, (Macc1); trans-acting transcription factor
4, (Sp4) and transmembrane protein 196 Mus musculus,
(Tmem196)] were not found to be dysregulated in
our data.
Our data are also in agreement with a previously re-
ported meta-analysis that was performed on DS patient
tissues, cell lines and mouse models at different develop-
mental stages [50]. Fifteen of the top 30 DS trisomic
genes with direct dosage effects reported in the meta-
analysis report [50] were also selected as DEGs in our
analysis [(Cbr1; carbonyl reductase, (Cbr3); Donson; Down
syndrome critical region gene 3, (Dscr3); E26 avian
leukemia oncogene 2, 3' domain, (Ets2); phosphoribosylgly-
cinamide formyltransferase, (Gart); Ifnar2; Ifngr2; Psmg1;
regulators of calcineurin 1, (Rcan1); Son; synaptojanin
1, (Synj1); Tmem50b, Ttc3 and Wrb)]. The expression
of dual-specificity tyrosine-(Y)-phosphorylation regulated
kinase 1a (Dyrk1a), a well-studied gene in DS individuals
and mouse models, has been found to be inconsistent
across various expression profiling studies involving the
brain of Ts1Cje mice. Dyrk1a was not differentially regu-
lated in our dataset and our finding is in agreement
Table 3 Summary of spatiotemporal RT-qPCR validations of 25 selected DEGs
Official
symbol Full gene name (ID) Probe set ID
Log2 expression of Ts1Cje normalized against disomic littermates
Microarray analysis RT-qPCR analysis
P1 P15 P30 P84 P1 P15 P30 P84
Cerebral Cortex
Atp5o
ATP synthase, H+ transporting,
mitochondrial F1 complex,
O subunit
1437164_x_at 0.58 0.71 0.72* 0.64 1.07 0.78* 0.28 0.77*
Brwd1
Bromodomain and WD repeat
domain containing 1
1433955_at 0.55 0.53 0.63 0.86*
0.44 0.44 0.70* 0.6
1452322_a_at 0.07 0.62 0.47 0.83*
Donson Downstream neighbor of SON 1426739_at 0.76 0.72 0.91** 0.78 0.89 0.61 0.70* 0.73
Dopey2 Dopey family member 2 1428330_at 0.68* 0.47 0.61 0.45 0.53 0.42 0.52* 0.56
Erdr1 Erythroid differentiation regulator 1 1452406_x_at 0.61 -1.14 5.61* 1.82 0.54 -0.64 5.85* 2.16
Ifnar1 Interferon (alpha and beta) receptor 1 1449026_at 0.8 0.8 1.17* 1.29* 0.63 0.57 0.44 0.66*
Ifnar2 Interferon (alpha and beta) receptor 2 1451462_a_at 0.7 0.9 0.99* 0.98 0.36 0.41 0.45 0.91*
Itgb8 Integrin beta 8 1436223_at -0.88 -1.02 -1.21** -0.7 -0.59 -0.90* -0.95* -0.88*
Itsn1 Intersectin 1 (SH3 domain protein 1A) 1452338_s_at 0.58 0.96 1.42** 1.66** 0.43 0.88 0.69* 0.57*
Morc3 Microrchidia 3 1420091_s_at 0.55 0.81** 0.64 0.66 0.7 0.39 0.59 0.78
Mrps6 Mitochondrial ribosomal protein S6 1424440_at 0.84** 0.62 0.73 0.35 1.11 0.49 0.57 0.54
Sod1 Superoxide dismutase 1, soluble 1440222_at 1.79* 1.47 1.41 1.79 0.13 0.07 -0.15 -0.16
Tmem50b Transmembrane protein 50B 1423707_at 0.78** 0.51 0.70* 0.46 1.12 0.62 0.56* 0.77*
Ttc3 Tetratricopeptide repeat domain 3 1448361_at 0.45 0.45 0.54* 0.43 0.78 0.68 0.45 0.45*
Cerebellum
Atp5o
ATP synthase, H+ transporting,
mitochondrial F1 complex,
O subunit
1416278_a_at 0.43 0.67** 0.82* 0.54
0.90 0.47 0.40 0.36
1437164_x_at 0.68* 0.74** 0.78 0.59
Brwd1
Bromodomain and WD repeat
domain containing 1
1427322_at 0.32 0.81* 0.84* 0.54
0.33 0.98 0.54* 0.421433955_at 1.17*** 0.81** 0.57 1.01***
1452322_a_at 0.14 0.37 0.22 0.94***
Cbr1 Carbonyl reductase 1 1460196_at 0.71 0.52 0.30 0.72* 0.58 0.67* 0.31 0.25
Donson Downstream neighbor of SON 1426739_at 0.82* 0.91** 0.75 0.75* 0.34 1.09 0.46 0.37
Dopey2 Dopey family member 2 1428330_at 0.58 0.83** 0.70* 0.59 0.50 0.65 0.52* 0.36
Erdr1 Erythroid differentiation regulator 1 1452406_x_at 0.67 -0.73 5.69* 1.34 -0.11 -0.31 4.63* 1.36
Hmgn1
High mobility group nucleosomal
binding domain 1
1422495_a_at 0.22 0.96** 0.49 0.68*
0.43 0.69 0.26 0.481438940_x_at 0.40 0.76* 0.24 0.54
1455897_x_at 0.49 1.07** 0.30 0.80
Ifnar1 Interferon (alpha and beta) receptor 1
1442222_at 0.45 1.12* 0.73 0.68
0.55 0.60 0.44 0.70*
1449026_at 0.55 0.67 0.85 1.10*
Ifnar2 Interferon (alpha and beta) receptor 2 1451462_a_at 0.61 0.90* 0.80 0.93* 0.53 0.62 0.44 0.80
Ifngr2 Interferon gamma receptor 2 1423558_at 0.67** 0.14 0.17 0.21 0.86 0.53 0.17 0.32*
Itgb8 Integrin beta 8 1436223_at -0.61 -1.35*** -1.22** -1.54*** -0.52 -1.05* -0.47 -1.69***
Itsn1 Intersectin 1 (SH3 domain protein 1A)
1421192_a_at 0.03 0.94* 1.16** 0.66
0.19 0.65 0.34 0.291435885_s_at 0.46 1.18* 0.25 0.50
1452338_s_at 0.44 0.99 0.80 1.30**
Kcnj6
Potassium inwardly-rectifying channel,
subfamily J, member 6
1451868_at -0.07 0.95 1.23* 0.33 0.31 0.79 0.32 0.16
Morc3 Microrchidia 3
1420091_s_at 0.78** 0.84*** 0.69* 0.55
0.17 0.46 0.24 0.59
1452224_at 0.82 0.99 1.21* 0.52
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Table 3 Summary of spatiotemporal RT-qPCR validations of 25 selected DEGs (Continued)
Mrps6 Mitochondrial ribosomal protein S6
1424440_at 0.89** 0.70* 0.89** 1.00***
0.97 0.74* 0.05 0.66*
1447585_s_at 1.13* 0.88 0.53 0.94
Paxbp1 PAX3 and PAX7 binding protein 1
1418007_at 0.55 1.32* 0.59 0.80
0.27 0.69 0.66* 0.38
1418008_at 0.56 1.45* 0.63 0.75
Smim11 Small integral membrane protein 11 1417402_at 0.90* 0.69 0.59 0.59 -0.24 0.76 -0.13 -0.39
Sod1 Superoxide dismutase 1, soluble 1440222_at 1.60 1.24 1.40 1.96** 0.15 0.17 0.06 -0.17
Son Son cell proliferation protein
1420952_at 0.36 1.28* 0.71 0.87
0.39 1.23 0.63* 0.441435862_at 0.35 1.04** 1.24** 0.78
1437924_at 0.28 0.96** 0.75 0.67
Stat1
Signal transducer and activator of
transcription 1 1420915_at
-0.30 0.40 0.06 1.03** -0.34 0.03 0.57 0.62
Tbata Thymus, brain and testes associated 1450281_a_at 0.22 0.97* -0.03 0.25 0.57 0.81* 0.57 0.47
Tmem50b Transmembrane protein 50B 1423707_at 0.83** 0.69* 1.07*** 0.71** 0.83 0.62 0.46 0.42
Ttc3 Tetratricopeptide repeat domain 3 1416484_at 0.60 0.39 0.74 0.87* 0.59 0.36 0.66* 0.38
Wrb Tryptophan rich basic protein 1460446_at 0.72* 0.90** 0.45 0.67* 0.61 0.66 0.68* 0.37
Hippocampus
Actg1 Actin, gamma, cytoplasmic 1 1415779_s_at -0.02 -0.07 -0.07 0.39* -0.16 -0.02 -0.02 0.18
Atp5o
ATP synthase, H+ transporting,
mitochondrial F1 complex,
O subunit
1416278_a_at 0.68 0.37 0.48 1.09***
0.64 0.23 0.39 0.59
1437164_x_at 0.71* 0.64* 0.74* 0.94***
Brwd1
Bromodomain and WD repeat domain
containing 1
1427322_at 0.78 0.26 0.52 1.11***
0.66 -0.36 0.33 0.451433955_at 0.39 0.70* 0.70* 0.91***
1452322_a_at 0.67* 0.46 0.68* 0.22
Cbr1 Carbonyl reductase 1 1460196_at 0.64 0.95** 0.72 0.74* 0.24 0.30 0.42 0.61*
Donson Downstream neighbor of SON 1426739_at 0.81* 0.65 0.63 0.92** -0.08 0.34 0.34 0.89**
Dopey2 Dopey family member 2 1428330_at 1.00*** 0.68* 0.85** 0.77** 0.57 -0.16 0.55* 0.55
Erdr1 Erythroid differentiation regulator 1
1439200_x_at 0.68 -0.94 4.72* 0.80
0.51 -1.27 5.36* 1.68
1452406_x_at 0.80 -1.12 5.77* 1.10
Hmgn1
High mobility group nucleosomal binding
domain 1
1422495_a_at 0.36 0.16 0.64 0.82** 0.04 0.10 0.51 0.31
Ifnar1 Interferon (alpha and beta) receptor 1 1449026_at 0.46 1.12* 0.84 0.75 -0.08 0.25 0.41 0.57*
Ifnar2 Interferon (alpha and beta) receptor 2
1427691_a_at 0.73 1.49* 0.91 0.50
0.07 0.08 0.43 0.501440169_x_at 1.22 1.49* 0.84 0.62
1451462_a_at 0.81 0.83 0.92* 1.43***
Itgb8 Integrin beta 8 1436223_at -1.19** -0.64 -1.04* -1.14** -1.11 -1.26** -0.92* -0.80*
Itsn1 Intersectin 1 (SH3 domain protein 1A)
1421192_a_at 1.01* 0.48 0.97* 1.04**
0.38 -0.23 0.36 0.73*
1425899_a_at 0.76 -0.54 0.18 1.67*
Kcnj6
Potassium inwardly-rectifying channel,
subfamily J, member 6
1425707_a_at -0.21 0.57 1.07* -0.06 0.96 0.17 0.07 0.66
Morc3 Microrchidia 3
1420091_s_at 0.64* 0.66* 0.78** 0.99***
-0.16 0.31 0.45 0.85*
1452224_at 1.20* 0.51 0.55 1.45**
Mrps6 Mitochondrial ribosomal protein S6
1424440_at 0.77* 0.72* 0.64 0.91**
0.46 0.50 0.55 0.38
1447585_s_at 0.61 1.15* 0.91 0.61
Son Son cell proliferation protein 1435862_at 0.99* 0.20 0.58 1.17** 0.73 0.07 0.44 0.84**
Tmem50b Transmembrane protein 50B 1423707_at 0.96*** 0.76** 0.84* 0.99*** 0.78 -0.01 0.61* 0.61
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Table 3 Summary of spatiotemporal RT-qPCR validations of 25 selected DEGs (Continued)
Ttc3 Tetratricopeptide repeat domain 3 1448361_at 0.33 0.63** 0.45 0.46 0.34 0.37 0.50 0.37
Wrb Tryptophan rich basic protein 1460446_at 0.56 0.85** 0.69 0.70* 1.00 0.26 0.44 0.63*
All selected DEGs are trisomic genes located on chromosome 16 except for Erdr1 (a disomic gene located on chromosome X), Itgb8 (a monosomic gene located
on chromosome 12), Sod1 (a trisomic gene located on chromosome 16, although one of the copies is non-functional due to truncation), and Stat1 (a disomic gene
located at chromosome 1).
*p<0.05, **p<0.01 and ***p<0.001 based on Empirical Bayes t-statistic test.
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sphere [34] and early postnatal Ts1Cje whole brains [33],
but this result is in contrast to those of Laffaire et al. [23],
who observed Dyrk1a over-expression in the cerebellum of
early postnatal Ts1Cje mice. According to our dataset,
Rcan1, which is located in the Down syndrome critical
region (DSCR), was over-expressed in P1 cerebral cortex
and P15 hippocampus of Ts1Cje mice. Rcan1-null mice
demonstrated deficits in spatial learning and memory, im-
plicating its role in late-phase long-term potentiation and
memory formation [51]. In addition, RCAN1-1S over-
expression in the hippocampal neuronal cell line HT22 cell
line resulted in hyperphosphorylation of tau [52], which
positions Rcan1 as an important candidate for further in-
vestigation in DS-related Alzheimer’s disease features.
Functional clustering of various DEGs based on DA-
VID ontologies highlighted a global dysregulation of
interferon-related molecular networks in all brain re-
gions attributed mainly to the dysregulated expression of
the trisomic genes Ifnar1 and Ifnar2. These genes code
for IFN beta-receptor subunits 1 and 2, respectively.
However, Ifngr2, which encodes one of the two subunits
of the IFN gamma receptor, was differentially upregu-
lated in the cerebellum only. A role for all 3 interferon
receptors and their dysregulation has been described in
mouse models of DS. For example, mouse fetuses that
are trisomic for MMU16 (Ts16), which includes the
interferon alpha and gamma receptor genes, showed
upon subsequent knockout of these genes improved
growth when compared to Ts16 fetuses and generatedFigure 7 Western blotting analysis of Ifnar1 (66 kDa), Ifnar2 (55 kDa)
(P84) Ts1Cje and wild type littermates. Each band represents each Ts1Ccortical neurons with similar viability to their euploid
counterparts [53]. In the present study, upregulation of
these receptors suggests that the Ts1Cje mouse would
have a lower response threshold or hyperresponsiveness
to interferons or cytokines that would result in activa-
tion of downstream intracellular signaling pathways con-
tributing to the observed neuropathology, particularly in
the cerebellum.
In addition to Ifnar1, Ifnar2 and Ifngr2, our analysis
showed that other Jak-Stat- associated genes such as
Stat1 (P84), Lepr (P1) and two interferon response factor
genes, Irf3 (P15) and Irf7 (P84), were upregulated in the
Ts1Cje cerebellum. Irf3 and Irf7 have been shown to
induce type 1 interferons, which subsequently stimu-
late Jak-Stat signal transduction pathways leading to up-
regulated transcription of various interferon-stimulated
genes [54-56]. Leptin and its receptor, Lepr, have been
shown to be involved in leptin-dependent adult hippo-
campal neurogenesis [57] and mediated neuroprotection
of dopaminergic cells via activation of Jak-Stat, mitogen-
activated protein kinases (MEK)/extracellular signal-
regulated kinases (ERK) and growth factor receptor-
bound protein 2 (GRB2) signaling pathways in a mouse
model of Parkinson’s disease [58]. The role of the Jak-
Stat signaling pathway in the brain, however, is unclear.
Jak-Stat signaling has recently been implicated in neuro-
genesis/cell-fate determination [59,60], astrogliogenesis
[61,62] and synaptic plasticity [63,64] within the nervous
system of rats and fruit flies, but not specifically in the
development and progression of neuropathology inand Stat1 (91 kDa) in the cerebral cortex and cerebellum of adult
je or wild type mouse in the respective brain region.
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STAT1 activities has been shown to promote astroglio-
genesis during the neurogenic phase of development
[61]. We have previously demonstrated that Ts1Cje mice
have a number of defects in adult neurogenesis, includ-
ing a severe reduction in the numbers of neurons pro-
duced and an increased number of astrocytes [29]. Our
current protein analysis further confirmed the over-
expression of Ifnar1 and Stat1 in the cerebellum of adult
(P84) Ts1Cje mice as compared to their wild type litter-
mates. Therefore, we hypothesize that over-activation of
Jak-Stat signal transduction, which is due to the increased
sensitivity towards interferons via over-expression of inter-
feron receptor, may lead to a preference for the glial-fated
path in Ts1Cje neural precursors that contributes to the
neuropathology observed in Ts1Cje mice. The role of the
trisomic genes Ifnar1, Ifnar2 and Ifngr2 and the disomic
gene Lepr in upregulation of Stat1, Irf3 and Irf7 and sub-
sequent activation of Jak-Stat signaling in the Ts1Cje
mouse brain, particularly the cerebellum, remains elusive
and warrants further investigation.
From the list of validated trisomic DEGs, Brwd1, Donson,
Tmem50b and Itsn1 were upregulated in all brain regions,
which concurs with previous studies [65-72]. Both Brwd1
and Donson are not well studied and have not been associ-
ated with the progression and development of neuropath-
ology in DS. Brwd1 encodes a nuclear protein that plays a
role in transcriptional regulation related to diverse bio-
logical functions [65,66]. Donson, on the other hand, en-
codes a protein of unknown function. Fusion transcripts
that are encoded by exons from Donson and another triso-
mic DEG, Atp5o, have been reported but their role/func-
tion also remains unknown [67]. Tmem50b encodes an
intracellular membrane protein expressed mainly in the
endoplasmic reticulum and Golgi apparatus of the rodent
brain [68]. At the subcellular level, Tmem50b is expressed
in rat and mouse glial fibrillary acidic protein (GFAP)-
positive cells and to a lesser degree in neuronal microtubule-
associated protein 2 (MAP2)- or beta-tubulin II-positive
cells in vitro, suggesting a role for this gene in astroglial
cell development or function. Upregulation of ITSN1
has been demonstrated previously in the prosenceph-
alon of DS fetuses compared with controls [69]. Itsn1 is
also expressed in both proliferating and differentiating
neurons in the mouse brain [69] and has been shown to
regulate endocytosis events probably via the formation
of clathrin-coated vesicles, which are important for re-
cycling synaptic vesicles [70]. Endocytosis anomalies
such as enlarged endosomes in neurons were identified
as an early neuropathological feature in the brain of
Ts65Dn mice and individuals with DS and Alzheimer’s
disease [71,72]. Over-expressed Itsn1 and amyloid beta
(A4) precursor protein (App) may contribute to the early
development of Alzheimer’s disease in DS individuals byaccelerating beta amyloid and neurofibrillary tangle accu-
mulation via increased endocytosis activity in neurons.
Our microarray data demonstrate that many other triso-
mic DEGs such as Atp5o, Cbr1, Dopey2, Erdr1, Hmgn1,
Morc3, Mrps6, Son and Wrb, are upregulated in Ts1Cje
mouse brain regions. The molecular and cellular functions
of these DEGs have not been comprehensively character-
ized in the brain and therefore their potential roles in the
onset and progression of neuropathology observed in DS
remain poorly understood. Of these DEGs, the expression
profiles of Cbr1, Dopey2, Erdr1, Hmgn1 and Mrps6 are in
agreement with previous studies of DS mouse models
[31,32,73-75]. The chromatin-binding protein Hmgn1 is a
negative regulator of methyl CpG-binding protein 2
(MeCP2) expression via chromatin structure changes and
histone modification in the MeCP2 promoter [76]. As
MeCP2 has widespread effects on gene expression, espe-
cially in neurological disease such as Rett syndrome [77],
over-expressed Hmgn1 will down-regulate MeCP2 expres-
sion, which may cause disruption in terms of downstream
gene expression that is necessary for normal brain develop-
ment. Dopey2 has been proposed as a candidate gene that
is responsible for mental retardation in DS individuals be-
cause its expression was found in brain regions that are in-
volved in learning and memory processes [75,78-80].
Transgenic mice over-expressing Dopey2 demonstrated in-
creased density of cortical cells suggesting that this protein
may play an important role in brain morphogenesis and
therefore may contribute to neuropathology of DS when
over-expressed [78,80]. These under-characterised DEGs
are important candidates that should be investigated further
to understand various neuropathological features of DS.
Conclusion
Our study aimed to define the disrupted molecular path-
ways caused by partial triplication of MMU16 during post-
natal brain development in the Ts1Cje mouse model of DS.
Global analysis of transcriptomes from different regions of
the Ts1Cje brain supported a gene-dosage effect of the
majority of the trisomic genes that led to the disruption of
the disomic genome. Interferon-related pathways were
identified as the most significantly dysregulated molecular
networks and these changes were attributed mainly to the
upregulation of the interferon receptors, which are encoded
by the trisomic genes Ifnar1, Ifnar2 and Ifngr2. Upregula-
tion of Ifnar1 and Stat1 proteins in the adult Ts1Cje
cerebral cortex and cerebellum suggests that interferon
receptor over-expression may lead to over-stimulation of
Jak-Stat signaling pathway. The role of interferon-mediated
activation or inhibition of signal transduction has been
well-characterized in various biological processes and dis-
ease models, including DS, but information pertaining to
its role in the development and function in the Ts1Cje or
DS brain remains scarce and warrants further investigation.
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